A Randomized 4-week Phase IIa Trial Evaluating the Efficacy, Safety, and Tolerability of GRT6005, a New Centrally Acting Analgesic, in Subjects With Pain Due to Diabetic Polyneuropathy.

Trial Profile

A Randomized 4-week Phase IIa Trial Evaluating the Efficacy, Safety, and Tolerability of GRT6005, a New Centrally Acting Analgesic, in Subjects With Pain Due to Diabetic Polyneuropathy.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Cebranopadol (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Grunenthal
  • Most Recent Events

    • 16 Jun 2017 A population PK analysis of cebranopadol using data from phase I and II trials, results published in the Clinical Pharmacokinetics
    • 05 Jun 2012 Actual patient number (189) added as reported by ClinicalTrials.gov.
    • 14 Apr 2012 New source identified and integrated (European Clinical Trials Database: EudraCT2010-022557-42).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top